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To investigate the pathogenic role of enteroaggregative Escherichia coli (EAggEC) among
human immunodeficiency virus–infected persons, 111 outpatients with and 68 without diar-
rhea were evaluated. Examination of stool samples included the HeLa cell adherence assay
and an EAggEC polymerase chain reaction (PCR) assay using primers complementary for
the plasmid locus CVD432. The pCVD432 genotype, adherence phenotype, and patient char-
acteristics were correlated with occurrence of diarrhea by multivariate analyses. EAggEC PCR
and adherence assays were positive in 7 (6%) and 24 (22%) patients with diarrhea and in 1
(1%) and 21 (31%) asymptomatic control patients, respectively. Clinical manifestations asso-
ciated with EAggEC PCR-positive isolates were nonspecific; EAggEC infections were inde-
pendent of CD4 lymphocyte counts. Of the pCVD432 genotype, 5 (71%) of 7 were resistant
to cotrimoxazole and ampicillin, and 1 strain was resistant to ciprofloxacin. Overall, pCVD432
PCR-positive E. coli was the most prevalent intestinal organism associated with diarrhea. The
adherence assay results did not correlate with diarrhea.
Human immunodeficiency virus (HIV)–associated diarrhea
frequently remains unexplained, despite comprehensive evalu-
ation, including examination of stool samples and endoscopy
[1]. An increasing proportion of patients may suffer from in-
testinal adverse effects of antiretroviral drugs, but the current
diagnostic approach may fail to detect relevant and possibly
treatable enteric pathogens. Enteroaggregative Escherichia coli
(EAggEC) are associated with acute or persistent diarrhea
among children in tropical and nontropical countries [2, 3] and
with foodborne outbreaks, nosocomial infections, and trave-
ler’s diarrhea [4]. Recently, EAggEC have been considered as
causes of HIV-associated diarrhea [5, 6]. In a study, EAggEC
were found more frequently in stool samples of HIV-infected
adults with diarrhea than in asymptomatic control patients and
appeared to be more often associated with intestinal disease
when immunodeficiency was more advanced [6]. Moreover,
eradication of EAggEC in HIV-infected patients with otherwise
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unexplained chronic diarrhea led to resolution or improvement
of symptoms in ∼80% of treated patients [7].
No widely accepted diagnostic methods to identify EAggEC
are available for the routine clinical laboratory. EAggEC is
defined by the “stacked brick” aggregative adherence pattern
in the HEp-2 or HeLa cell adherence assay [4, 8], the most
reliable diagnostic means [6]. Molecular probes to detect dif-
ferent presumed virulence factors of EAggEC have been de-
veloped, but neither method has enjoyed frequent application,
and a comparison of cell culture assays and molecular diag-
nostics often have considerable discrepant results [2, 6, 9, 10].
This may be explained, in part, by results of phylogenetic anal-
yses that show a significant strain-to-strain heterogeneity and
suggest that EAggEC strains comprise a heterogeneous set of
pathogens [4]. Differing virulence by EAggEC strain has been
postulated, because healthy volunteers who ingested EAggEC
did not consistently develop diarrhea [11]. In the present study,
we had 4 goals: (1) to evaluate the prevalence of EAggEC
among HIV-infected patients with and without diarrhea, (2) to
describe the clinical manifestations associated with EAggEC,
(3) to compare the EAggEC polymerase chain reaction (PCR)
assay (using primers complementary for pCVD432) with the
HeLa cell adherence assay, and (4) to determine the antibiotic
resistance of EAggEC in this patient group.
Patients and Methods
Study design. We collected stool samples and clinical data for
all patients at the University Hospital HIV outpatient clinic (Zu-
rich) who were evaluated for diarrhea (September 1996 to August
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Table 1. Patient characteristics and intestinal organisms detected
among human immunodeficiency virus (HIV)–infected patients with
and without diarrhea.
Characteristics
With
diarrheaa
Without
diarrheaa
All patients 111 (100) 68 (100)
Women patients 11 (10) 1 (2)
Median age in years (range) 39 (25–79) 36 (27–61)
Mode of HIV acquisition
Homosexual contact 75 (68) 45 (66)
Injection drug use 17 (15) 13 (19)
Heterosexual contact and other 19 (18) 10 (14)
No. with AIDS at baseline 40 (36) 20 (29)
Median CD4 lymphocytes/mm3 (range) 188 (3–995) 259 (15–1028)
!50 16 (14) 7 (10)
50–200 42 (38) 17 (25)
1200 53 (48) 44 (65)
Median HIV-1 RNA (range),
log10 copies/mL 3.0 (!2.6–6.4) 3.4 (!2.6–6.3)
Antiretroviral triple therapy 99 (89) 51 (75)
Pneumocystis carinii and Toxoplasma
gondii chemoprophylaxis 46 (41) 18 (26)
No. with diarrhea without identifiable
pathogen 77 (69) 64 (95)
No. of intestinal pathogens 40b 5c
Bacteria
Enterovirulent E. coli
EAggEC (PCR positive)d 7 (6)e 1 (1)f
Enteropathogenic E. coli 5 (5) 2 (3)
Enterotoxigenic E. coli 0 2 (3)
Verotoxin-producing E. coli 1 (1) 0
Clostridium difficile 6 (5) ND
Campylobacter jejuni 3 (3) ND
Salmonella species 2 (2) ND
Aeromonas species 1 (1) ND
Plesiomonas species 1 (1) ND
Shigella species 0 ND
Protozoa
Giardia lamblia 6 (5) ND
Enterocytozoon bieneusi 3 (3) ND
Cryptosporidia species 2 (2) ND
Entamoeba histolytica 1 (1) ND
Leishmaniag 1 (1) ND
Cytomegalovirusg 1 (1) ND
NOTE. Data are no. (%) unless otherwise indicated. EAggE, enteroaggre-
gative Escherichia coli; ND, not done; PCR, polymerase chain reaction.
a No statistical significant difference between groups with and without diarrhea
with regard to all variables.
b Forty pathogens identified in 33 patients (6 patients with dual intestinal
infection).
c Five pathogens identified in 4 patients (1 patient with dual infection).
d Difference between groups, .P p .16
e Includes 2 patients with coinfections due to EAggEC and enteropathogenic
E. coli or Enterocytozoon bieneusi, respectively.
f Double infection due to EAggEC and enteropathogenic E. coli.
g Detected in intestinal biopsies.
1998) [1]. Patients answered a questionnaire on possible risks for
diarrhea and were prospectively followed within the Swiss HIV
Cohort Study [12]. Control patients were HIV-infected persons who
did not have diarrhea for >4 weeks.
Evaluation of diarrhea. Patients with >2 loose or watery stools
per day for >3 days underwent a standardized examination of stool
samples (table 1) [1]. Stool samples of patients with diarrhea andcontrol
patients were tested for verotoxin-producing, enteropathogenic, and
enterotoxigenic E. coli [13]. Upper endoscopy or ileocolonoscopy was
performed, if chronic diarrhea remained unexplained.
EAggEC cell adherence assay. Four biochemically confirmed
E. coli colonies were assayed by HeLa cell adherence assay [6]:
HeLa cells (American Type Culture Collection, Rockville, MD)
were suspended in MEM with 10% fetal calf serum (FCS) without
antibiotics, seeded in 8-well chamber slides (Lab-Tek; Nunc, Na-
perville, IL), and were incubated overnight at 377C with 5% CO2.
E. coli strains to be tested were grown overnight at 377C in 2 mL
of trypticase soy broth (Becton Dickinson Microbiology Systems,
Cockeysville, MD), were washed, and were resuspended in PBS.
The medium in the chamber wells was replaced with 200 mL of
MEM with 1% D-mannose without FCS and antibiotics. We added
20 mL of the E. coli suspension (0.5 MacFarland U) to chamber
wells, which were incubated for 3 h. Subsequently, the slide with
the monolayers was washed 4 times with PBS, fixed with methanol,
and stained with Giemsa. A search for aggregative adherence pat-
tern was performed in a blinded fashion by 2 investigators.
Molecular identification of EAggEC. Amplification with prim-
ers pCVD432/start and pCVD432/stop was performed with bac-
terial growth from MacConkey agar or with individual E. coli
colonies, as described elsewhere [10].
Antibiotic susceptibility testing. Disk-diffusion susceptibility
testing was performed on Mueller-Hinton agar plates, according
to guidelines of the National Committee for Clinical Laboratory
Standards.
Statistical analysis. Data were compared by the 2-tailed x2 or
Fisher’s exact tests. Continuous variables were compared by the
Wilcoxon rank sum test. EAggEC genotype and phenotype and
demographic and clinical variables were correlated with diarrhea
by using multivariate logistic regression models (version 6.0 soft-
ware; Stata, College Station, TX).
Results
Study participants. We enrolled 111 patients with diarrhea and
68 asymptomatic control patients who were equivalent at baseline
for demographic variables and HIV disease stage (table 1).
Intestinal pathogens. Enteric pathogens were detected
among 31% of patients with diarrhea (table 1). Neither ileo-
colonoscopy of 17 patients nor esophagogastroduodenoscopy
of 18 of 46 patients with chronic diarrhea revealed additional
pathogens, except in 1 patient with dual intestinal infection due
to Leishmania organisms and cytomegalovirus.
EAggEC PCR and adherence assay. E. coli was grown from
76 stool samples (68.5%) of 111 patients with diarrhea and from
51 stool samples (75%) of 68 control patients (table 2). The
EAggEC cell adherence assay was positive in stool samples of
24 (22%) patients with diarrhea and in 21 (31%) control pa-
tients. EAggEC PCR was positive in 7 (6%) patients with di-
arrhea and in 1 asymptomatic control. Eight PCR-positive
EAggEC were identified in specimens prepared from a swab of
the MacConkey agar plate. When individual E. coli colonies
were examined by PCR, EAggEC was detected in >1 colony
from 5 patients. Three of the PCR-positive isolates were cell–
adherence assay negative.
EAggEC-associated clinical manifestations. One asympto-
matic carrier of pCVD432 PCR-positive EAggEC (CD4 lympho-
cytes, 1028/mm3) remained asymptomatic during follow-up. The
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Table 2. Detection of enteroaggregative Escherichia coli (EAggEC) in stool samples by using pCVD432
polymerase chain reaction (PCR) and cell adherence assay.
Patient group, specimens
for EaggEC PCR Total
E. coli
culture
positive
EAggEC adherence
assay positive
EAggEC adherence
assay negative
PCR
positive
PCR
negative Total
PCR
positive
PCR
negative Total
With diarrhea
MacConkey agar plate 111 (100) 76 (68)
Swab 4 (4) 20 (18) 24 (22) 3 (3) 49 (44) 52 (47)
Individual E. coli colonies 3 (3)a 21 (19) 24 (22) 2 (2)b 50 (45) 52 (47)
Without diarrhea
MacConkey agar plate 68 (100) 51 (75)
Swab 0 21 (31) 21 (31) 1 (1) 29 (43) 30 (44)
Individual E. coli colonies 0 21 (31) 21 (31) NDc 30 (44) 30 (44)
NOTE. Data are no. (%) of patients. ND, not determined.
a Identical with 3 of 4 patients with EAggEC PCR–positive swab samples.
b Identical with 2 of 3 patients with EAggEC PCR–positive swab samples.
c EAggEC adherence assay was not done, because none of the 4 bacterial colonies obtained from MacConkey agar plate
was biochemically found to be E. coli.
7 patients with diarrhea and EAggEC PCR-positive stool samples
presented with nonspecific symptoms, including watery diarrhea
(86%), abdominal pain (43%), and low-grade fever (57%). Bloody
diarrhea was not reported. Hematology or serum chemistry did
not reveal any abnormalities associated with EAggEC infection.
The following patient groups with diarrhea were compared
with regard to clinical presentation: EAggEC PCR positive,
PCR negative, EAggEC adherence assay positive, adherence
assay negative, other intestinal pathogens, and no pathogen
detected. No differences were found, except that patients with
pCVD432 PCR-positive stool samples more frequently com-
plained of fever. CD4 lymphocyte counts of patients with di-
arrhea and PCR-positive EAggEC (median, 141/mm3; range:
3–995/mm3), adherence-positive isolates (median, 264 mm3;
range, 3–842/mm3), or other intestinal bacterial infections (me-
dian, 179/mm3; range, 6–843/mm3) were similar but significantly
higher than in patients with enteric opportunistic infections
(median, 17/mm3; range, 3–83/mm3).
The median follow-up was 20 months (range, 5–34 months).
Of the 7 patients with PCR-positive EAggEC and diarrhea at
baseline, 4 continued to have chronic persistent or chronic in-
termittent diarrhea, whereas diarrhea stopped during follow-
up among 3 patients. All patients were receiving antiretroviral
therapy, including a protease inhibitor, throughout the follow-
up period. We observed no clear response to antibiotic treat-
ment, although diarrhea improved or ceased in most patients
during follow-up.
Correlation of EAggEC and diarrhea. Multivariate analysis
showed a correlation between antiretroviral therapy and di-
arrhea ( ) and an association between the pCVD432P p .02
genotype and diarrhea ( ). The result of the adherenceP p .078
assay, demographic variables, CD4 lymphocytes, HIV-1 RNA,
and chemoprophylaxis were not predictive for diarrhea.
Antibiotic resistance of pCVD432-positive EAggEC. Sus-
ceptibility testing of 13 different antibiotics showed resistance
to trimethoprim-sulfamethoxazole (71%), ampicillin (71%), and
cefalotin (43%). There was intermediate resistance to amoxi-
cillin plus clavulanate (43%) and cefamandole (29%). One
EAggEC PCR-positive isolate was resistant to ciprofloxacin.
Discussion
By using a PCR with primers complementary for the plasmid
locus CVD432 [10], we detected EAggEC in 1 (1%) of 68 HIV-
infected patients with and 7 (6%) of 111 without diarrhea, in-
dicating a pathogenic potential of EAggEC in this patient group.
The results of the EAggEC adherence assay, in contrast, did not
correlate with diarrhea, which suggests that different EAggEC
strains of heterogeneous virulence may exist. We could not iden-
tify risks for infection with EAggEC, such as source of drinking
water, food, contact with persons with diarrhea, pets, or travel.
As reported elsewhere [6], we also found a high rate of resistance
to ampicillin, trimethoprim-sulfamethoxazole, and other anti-
biotics, which may be a consequence of trimethoprim-sulfameth-
oxazole chemoprophylaxis. A link between antibiotic resistance
and virulence of EAggEC strains has been suggested [14].
Although EAggEC PCR-positive E. coli was the most prev-
alent intestinal organism associated with diarrhea, we were un-
able to definitively determine a causal relationship between its
presence and diarrhea because of the low number of patients
evaluated, and because most patients were on antiretroviral
therapy, including protease inhibitors, which are associated with
persistent diarrhea. Indeed, by multivariate analysis, we found
antiretroviral therapy to be the strongest predictor of diarrhea.
EAggEC have been defined phenotypically by their property
to aggregate in the HEp-2 or HeLa tissue culture adherence assay.
Different DNA probes to identify E. coli carrying potential vir-
ulence traits that encode for adherence have been developed, but
none of the factors has been consistently associated with the
results of the adherence assay, clinical variables (e.g., diarrhea),
or has been detected in most EAggEC strains from diverse geo-
graphic areas. Thus, the laborious and demanding cell adherence
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assay remained the reference standard for identification of
EAggEC. However, phylogenetic analyses of EAggEC indicate
that phenotypically characterized EAggEC include genotypically
different, presumably pathogenic and nonpathogenic organisms.
Furthermore, clinical studies show that nonpathogenic EAggEC
and non-EAggEC E. coli strains may exhibit the aggregative
adherence pattern [2, 4].
The DNA fragment probe (CVD432) derived from the ag-
gregative adherence plasmids of E. coli strains 17-2 and 042 is
highly specific in detecting EAggEC [9]. Subsequently, a sen-
sitive and specific PCR assay that uses primers complementary
for pCVD432 was developed [10]. This assay identified 86% of
reference EAggEC strains positive by the HEp-2 cell adhesion
assay and was positive in only 0.96% of other diarrheagenic E.
coli. However, some CVD432 probe–negative strains also carry
an aggregative adherence plasmid, and the association of in-
testinal illness and CVD432 PCR–positive strains has not con-
sistently been established. For example, Okeke et al. [2] found
that only 26% of EAggEC obtained from Nigerian children
hybridized with the CVD432 probe. Also, the prevalence of 8
adherence-encoding, plasmid-derived gene probes and 2
chromosomal gene probes did not differ between case and con-
trol patients, except that the aggregative adherence fimbrial
subunit (AAF/II) was detected more frequently in EAggEC
isolated from Nigerian children with diarrhea [2]. The EAST/
1 heat-stable toxin may be linked to enterotoxicity for EAggEC,
enteropathogenic E. coli, and enterohemorrhagic E. coli but
cannot be used for specific screening for EAggEC [15].
Epidemiologic studies of EAggEC in western Europe that
used pCVD432 PCR found a prevalence of 2% in German
infants with diarrhea [3] and 6.4% among Austrian children
and adults with diarrhea [16], but, to the best of our knowledge,
no data on probe-positive E. coli among HIV-infected patients
are available [3]. In a previous investigation on EAggEC, in-
cluding cohorts of HIV-infected patients in Boston and Zurich,
the HeLa cell assay demonstrated adherence in E. coli samples
of 44% of patients with and 30% without diarrhea ( )P p .05
[6]. The CD4 lymphocyte counts of patients with EAggEC and
diarrhea were significantly lower than among those without
diarrhea ( ), which suggests that EAggEC may representP p .02
an opportunistic pathogen. In the present study, we could not
duplicate these results using the same HeLa cell adherence as-
say. Furthermore, we found no significant differences with re-
gard to CD4 cell count among patients with adherence-positive
E. coli, associated with or without diarrhea, respectively, and
adherence-negative E. coli.
EAggEC may be a clinically relevant pathogen that causes
nonspecific intestinal disease, including acute or persistent wa-
tery diarrhea, abdominal pain, and often fever, not only among
severely immunodeficient patients but also among HIV-infected
persons whose cellular immunity was improved during anti-
retroviral therapy. Unfortunately, no widely accepted routine
diagnostic technique is available that reliably detects all patho-
genic EAggEC. Our data suggest that the pCVD432 PCR, pos-
sibly in combination with other probes including AAF/II [2],
may be useful for diagnostic evaluation of HIV-infected adults
with diarrhea, although such probes may miss a fraction of
EAggEC. Further studies are required to assess the role of
antibiotic treatment and the clinical impact of the high rate of
antibiotic resistance of EAggEC strains.
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